3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
40
Phase 3
28
Phase 4
4
Phase 1
4
Phase NA
2
Phase EARLY_PHASE1
2
Phase 1/2
2
Phase 2/3
1
Status
Recruiting
1
Completed
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Breast
2
Head & Neck
1
Gynecologic
1
Conditions
Breast Neoplasms
2
Uterine Cervical Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Ovarian Neoplasms
1
Neoplasms by Site
1
Neoplasms
1
Hereditary Sensory and Autonomic Neuropathies
1
Head and Neck Neoplasms
1
Endometrial Neoplasms
1
Breast Diseases
1
Interventions
pembrolizumab
210
Cyclophosphamide
122
Nivolumab
109
Carboplatin
92
fludarabine
81
Gemcitabine
76
Specimen Handling
74
Bevacizumab
72
venetoclax
70
Injections
70
Magnetic Resonance Spectroscopy
67
Dexamethasone
66
Paclitaxel
64
Biopsy
59
atezolizumab
56
Cisplatin
53
Ipilimumab
50
Temozolomide
45
Docetaxel
42
Azacitidine
42
Pemetrexed
41
Lenalidomide
41
Oxaliplatin
40
Rituximab
39
Radiotherapy
39
Fluorouracil
39
Cetuximab
37
durvalumab
36
Cytarabine
36
Capecitabine
36
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 1/2
×
Tamoxifen
×
1 year
×
Clear all
NCT05768139
2026-06-04
PIKALO-1
Eli Lilly and Company
Phase 1/2
Recruiting
880 enrolled
NCT03280563
2025-11-10
MORPHEUS HR+BC
Hoffmann-La Roche
Phase 1/2
Completed
144 enrolled
25 charts